Immuneering (IMRX) Cash from Operations (2020 - 2026)
Immuneering (IMRX) posted quarterly Cash from Operations of 18433444.0 for Q1 2026, down 30.91% year-over-year from 26681654.46 in Q1 2025, and down 87.32% quarter-over-quarter from 9840598.0 in Q4 2025.
Immuneering (IMRX) Cash from Operations (2020 - 2026) Analysis & Trends
Immuneering's Cash from Operations history runs 7 years deep, the most recent figure standing at 18433444.0 for Q1 2026.
- In Q1 2026, Cash from Operations fell 30.91% year-over-year to 18433444.0; the TTM figure through Mar 2026 stood at 49697401.0 (up 7.26% YoY), while the FY2025 annual figure was 45344595.0, up 17.55% from the prior year.
- Cash from Operations for Q1 2026 stood at 18433444.0, down from 9840598.0 in the prior quarter.
- The five-year high for Cash from Operations was 9446124.0 in Q2 2025, with the low at 18433444.0 in Q1 2026.
- The 5-year median for Cash from Operations is 11977235.0 (2025), against an average of 12461618.18.
- The sharpest annual moves came in 2022 and 2025: Cash from Operations slumped 100.02% in 2022, then soared 32.18% in 2025.
- Immuneering's Cash from Operations stood at 11748614.0 in 2022, then fell by 0.23% to 11775201.0 in 2023, then dropped by 23.23% to 14510513.0 in 2024, then surged by 32.18% to 9840598.0 in 2025, then slumped by 87.32% to 18433444.0 in 2026.
- Business Quant data shows IMRX's Cash from Operations at 18433444.0 in Q1 2026, 9840598.0 in Q4 2025, and 11977235.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Immuneering | 327.37 Mn | 327.37 Mn | - | -16.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.50 Mn |
| Jun 30, 2026 | -16.50 Mn |
| Mar 31, 2026 | -18.43 Mn |
| Mar 31, 2026 | -18.43 Mn |
| Dec 31, 2025 | -9.84 Mn |
| Dec 31, 2025 | -9.84 Mn |
| Sep 30, 2025 | -11.98 Mn |
| Sep 30, 2025 | -11.98 Mn |
| Jun 30, 2025 | -9.45 Mn |
| Jun 30, 2025 | -9.45 Mn |
| Mar 31, 2025 | -14.08 Mn |
| Mar 31, 2025 | -14.08 Mn |
| Dec 31, 2024 | -14.51 Mn |
| Dec 31, 2024 | -14.51 Mn |
| Sep 30, 2024 | -13.47 Mn |
| Sep 30, 2024 | -13.47 Mn |
| Jun 30, 2024 | -11.53 Mn |
| Jun 30, 2024 | -11.53 Mn |
| Mar 31, 2024 | -15.49 Mn |
| Mar 31, 2024 | -15.49 Mn |